登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600025 证券简称：华能水电 公告编号：2026-004 华能澜沧江水电股份有限公司 关于控股股东之一致行动人增持股份 及后续增持计划的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 华能澜沧江水电股份有限公司（以下简称"公司"或"华能水电"）于2026年2月24日收到公司控股股东 中国华能集团有限公司（以下简称"华能集团"）之一致行动人华能结构调整1号证券投资私募基金（以 下简称"华能结构调整基金"）管理人天津华人投资管理有限公司的通知，华能结构调整基金于2026年2 月24日通过上海证券交易所集中竞价方式增持了公司3,276,000股A股股份，增持股份占公司总股本的 0.0176%（"本次增持"）。公司控股股东华能集团直接及间接持有华能结构调整基金92.50%股权，为华 能集团的一致行动人。 ● 华能结构调整基金计划自本公告披露之日起6个月内继续通过上海证券交易所系统允许的方式增持公 司A股股份，累计增持金额不低于1亿元且不 ...

格隆汇2月23日｜通策医疗(600763.SH)公告称，公司董事长王毅、董事黄浴华、董秘张华、财务总监徐 国喜、其他管理人员赵敏计划自本次增持之日起6个月内，以自有资金或自筹资金通过上海证券交易所 交易系统以集中竞价交易方式增持公司股份合计不低于600万元，不超过1200万元。本次增持未设置价 格区间。增持主体基于对公司未来持续发展的信心和对公司长期投资价值的认可。 ...

这家智慧招采领域的龙头企业累计回购股份182.72万股，占公司总股本的0.57%，回购成交的最高价为31.15元/股，最低价为24.21元/股，回购均价为27.01元/ 股，支付的资金总额达到4935.67万元。 回购方案于2025年9月24日启动，计划使用自有资金3000万元至5000万元，实际执行金额接近上限。 这些回购的股份将全部用于员工持股计划或股权激励。 春节前的资本市场总是充满变数，当港股市场特别是互联网科技股表现疲软时，A股市场却出现了另一番景象。 2026年1月下旬至2月上旬，就在春节假期临近之际，9家行业龙头公司不约而同地采取了行动。 新点软件在2026年2月13日发布公告，宣布公司已完成股份回购计划。 回购的股份将在未来用于股权激励、员工持股计划或转换公司可转债。 衢州东峰新材料集团在2026年2月12日披露了回购报告书。 这家国资控股的新材料与医药包装企业计划使用自有资金，通过集中竞价交易方式回购公司股 份，回购金额区间为5000万元至1亿元。 回购价格上限设定为6.48元/股，按照这个价格测算，预计回购股份数量约为771.60万股至1543.21万股，占公司总股 本的比例为0.40%至 ...

香港联交所最新资料显示，2月11日，DA Wolf Investments I Limited增持德林控股（01709）50万股，每 股作价1.64港元，总金额为82万港元。增持后最新持股数目约为5.64亿股，持股比例为27.23%。 来源：新浪港股 ...

Group 1 - The core viewpoint of the article highlights two significant developments for the company, including a share increase by a major shareholder and the board's decision to apply for a soybean oil delivery warehouse qualification [1] Group 2 - On February 5, 2026, the company announced that a concerted action party of the controlling shareholder, Hunan Xingchuang Investment Management Co., Ltd., completed its share increase plan, acquiring a total of 5.4797 million shares, which represents 1.59% of the company's total share capital. This move may reflect the major shareholder's confidence in the company's long-term value [2] Group 3 - On February 3, 2026, the company held its 12th meeting of the fourth board of directors, where it reviewed a proposal to apply for soybean oil delivery warehouse qualification from the Dalian Commodity Exchange. If approved, this could enhance the company's storage and trading capabilities within the oilseed industry chain, providing support for future business expansion [3] - Additionally, the company's Q3 2025 report indicated stable performance, with a year-on-year increase of 93.69% in net profit attributable to shareholders for the first three quarters. However, attention is needed regarding the impact of raw material cost fluctuations and changes in consumer trends on the fundamentals [3]

Group 1 - The company announced that its executive director, chairman, and CEO, Mr. Luo, purchased a total of 1 million shares in the open market on February 6, 2026, representing approximately 0.05% of the company's total issued shares, at an average price of about HKD 2.72 per share [1] - Following the purchase, Mr. Luo directly and indirectly holds a total of 927 million shares, which accounts for approximately 44.32% of the company's total issued shares as of the announcement date [1] - Mr. Luo has also been granted 30 million share options under the share option scheme, which he has not exercised as of the announcement date [1] Group 2 - The board believes that conducting share buybacks under the current market conditions demonstrates the company's confidence in its business outlook and prospects, ultimately benefiting the company and creating value for shareholders [2] - The share buyback will be conducted when deemed appropriate and in the overall interest of the company and its shareholders [2] - The company may consider further share buybacks in accordance with all applicable laws and regulations at an appropriate time [2]

Group 1 - The company announced the abandonment of its preemptive rights regarding the transfer of shares in its subsidiary, Shanghai Yingshuang Electric Motor Technology Co., Ltd. (Yingshuang Technology), to an associated party, Shanghai Chuanghe Venture Capital Partnership (Limited Partnership) [1][2] - The total transfer price for the shares being sold by the shareholders of Yingshuang Technology amounts to RMB 30,000,190.01 [1][2] - The transaction has been approved by the company's board of directors and does not require shareholder approval [2] Group 2 - On February 4, 2026, the company signed relevant documents related to the share transfer, and the share transfer registration was completed on February 5, 2026 [3] - The shareholding structure of Yingshuang Technology has changed as a result of this transaction, with the details provided in the share register from the Shanghai Equity Custody Registration Center [4] Group 3 - The shares being transferred are free from any pledges or restrictions, and there are no ongoing litigations or judicial measures affecting the transfer [6] - The target company, Yingshuang Technology, is not listed as a dishonest executor [7] Group 4 - The company has completed a share repurchase plan, acquiring a total of 4,379,700 shares, which represents approximately 0.85% of the total share capital [18] - The repurchase was conducted at an average price of RMB 22.84 per share, with a total expenditure of RMB 100,015,473.00 [18] - The repurchased shares will be canceled, and the registered capital will be reduced accordingly [21][22] Group 5 - The company’s major shareholders, Guotou High-Tech Investment Co., Ltd. and its associated party, China Guotou High-Tech Industry Investment Co., Ltd., have increased their holdings by 172,370 shares, accounting for 0.34% of the total share capital [25] - The total amount spent on the share increase was RMB 40,013,819.00, exceeding the minimum target set in the increase plan [25][27]

Core Viewpoint - The actual controller of Baolingbao Biotech Co., Ltd., Mr. Dai Sichong, has expanded the shareholding plan to include a new entity, CEDARWALK BIOTECH HONG KONG LIMITED, to facilitate the acquisition of shares in the company [1][2]. Summary by Sections Shareholding Plan Overview - The original plan was to increase shareholding by 18,488,369 shares (5% of total shares) to a maximum of 36,976,738 shares (10% of total shares) starting from October 8, 2024, for a period of six months [1]. - The plan has been extended by 12 months, now set to conclude on April 7, 2026, while other details remain unchanged [2]. Addition of New Entity - CEDARWALK BIOTECH HONG KONG LIMITED has been added as a new entity to the shareholding plan, which is controlled by Mr. Dai Sichong [2][3]. - This entity will operate through a specific investment account managed by Guotou Securities Asset Management (Hong Kong) [2]. Shareholding Changes - As of February 4, 2026, the cumulative shares acquired by Shenzhen Songjing Investment Partnership and CEDARWALK BIOTECH HONG KONG LIMITED amount to 6,375,700 shares, representing 1.67531% of the total shares [3]. - The total shares acquired from November 2025 to February 2026 reached 5,076,300 shares, increasing the combined holding to 13.99607% [4]. Compliance and Commitments - The shareholding plan complies with relevant laws and regulations, ensuring that it does not affect the company's listing status or control [6]. - CEDARWALK BIOTECH HONG KONG LIMITED has committed to not reducing its holdings for six months post-acquisition [6].

Group 1 - The core point of the article is that Tianyao International Co., Ltd., a controlling shareholder of Darentang (600329.SH), has acquired 82,200 S shares of the company, representing 0.0107% of the total share capital, through the Singapore Exchange on February 4, 2026 [1] - Tianyao International expresses confidence in Darentang's future development prospects and recognizes its long-term investment value [1] - The company plans to increase its stake in Darentang by up to 1% of the total share capital within the next six months, with a purchase price not exceeding 4 USD per share [1] Group 2 - The planned investment amount for the additional shares is between 14.3 million RMB and 28.59 million RMB, including the amount from the current acquisition [1]

Group 1 - Tian Pharmaceutical announced that Tianyao International Limited purchased 82,200 shares of the company's S shares on February 4, 2026, accounting for 0.0107% of the total share capital [1] - Tianyao International plans to increase its stake in Tian Pharmaceutical by up to 1% of the total share capital within the next six months, through the Singapore Exchange trading system [1] - The price condition for the planned share purchase is set at no more than 4 USD per share, with the total investment amount ranging from 14.3 million RMB to 28.59 million RMB, including the amount from the current purchase [1]